ICU to boost critical care line with Hospira deal
This article was originally published in Clinica
In a bid to focus on its core technologies, specialty pharmaceutical and medication delivery firm Hospira is to divest its critical care product line to ICU Medical in a $35m cash deal. The transaction, which is expected to close during the third quarter of 2009, is part of Hospira’s plan to focus on its injectable pharmaceuticals and medication management systems. ICU had previously been the manufacturer of Hospira’s critical care offering, which includes invasive vascular and cardiac monitoring systems, angiography kits and Transpac disposable pressure transducers, since the two firms struck a manufacturing, commercialisation and development agreement in 2005. ICU claims that the deal will be accretive to earnings in fiscal 2009.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals